

Information regarding fund changes

The Luxembourg-domiciled SEB Concept Biotechnology merges with the Swedish-domiciled SEB Läkemedelsfond

Information for you as an investor in the receiving fund

As an investor, you are not required to take any action concerning this merger. The value of your investment will not be affected, but it is important for you to be aware of the merger.

We, at SEB Funds AB (the “Management Company”), will merge the Luxembourg-domiciled SEB Concept Biotechnology (the merging fund) with the Swedish-domiciled SEB Läkemedelsfond (the receiving fund). The merger will be effective from 8 September 2025.

The merger aims to simplify and streamline the fund offering while enhancing the efficiency of fund management.

How you as a customer are affected

This is a merger by absorption, in which the holdings and liabilities of the merging fund will be transferred to the receiving fund. As a result, the merging fund will cease to exist.

The merger will not have any material impact on the asset mix of the receiving fund, which will continue to follow the same investment objectives and strategy as previously. Furthermore, no significant changes will be required to the fund before or after the merger, and the fund's fees will remain unaffected. Accrued income will be considered in the valuation of the merging fund, and the merger will not result in any dilutive effects on the fund's performance. Ongoing reporting on the fund will remain unchanged.

The merging fund will be dissolved. SEB Funds AB will cover any costs related to legal, advisory, and administrative actions arising from the merger.

Rights and trading information

The receiving fund will not close during the merger process. If you wish to redeem your holdings in the fund before the merger, please note the following:

Important dates

- **5 September 2025:** The last opportunity to redeem your holdings in the receiving fund before the merger, prior to the cut-off time on this date.
- **8 September 2025:** The merger takes effect.

As usual, no fee is charged for redemption or sale of fund units. The merger itself will have no tax effect on you as a participant. However, redemption may have tax implications, and we recommend contacting your adviser for more information.

Unit classes and ISINs for the receiving fund, SEB Läkemedelsfond

Unit class	ISIN
A	SE0000984122
B	SE0023848122
C (EUR)	SE0024788731
D (EUR)	SE0024788749
E (USD)	SE0024788756
F (EUR)	SE0024788764
G (USD)	SE0024788772

Additional information

The merging fund is domiciled in Luxembourg, while the receiving fund is domiciled in Sweden, making this a cross-border merger. The regulations governing both the merging fund and the receiving fund are primarily based on European Union legislation. The merger has been approved by the Luxembourg financial regulator – CSSF and the Swedish financial regulator – Finansinspektionen.

Product documentation for the receiving fund is available (in Swedish) on our website, seb.se/fonder.

To obtain free access to the depositary institution's statement and auditor's report, or for additional information about the merger, please contact us at (+46) 771-365 365.